trichostatin-a has been researched along with Macular-Degeneration* in 1 studies
1 other study(ies) available for trichostatin-a and Macular-Degeneration
| Article | Year |
|---|---|
Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells.
Our study assesses the effects of anti-VEGF (Vascular Endothelial Growth Factor) drugs and Trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC) activity, on cultured ARPE-19 (Adult Retinal Pigment Epithelial-19) cells that are immortalized human retinal pigment epithelial cells. ARPE-19 cells were treated with the following anti-VEGF drugs: aflibercept, ranibizumab, or bevacizumab at 1× and 2× concentrations of the clinical intravitreal dose (12.5 μL/mL and 25 μL/mL, respectively) and analyzed for transcription profiles of genes associated with the pathogenesis age-related macular degeneration (AMD). HDAC activity was measured using the Fluorometric Histone Deacetylase assay. TSA downregulated Topics: Bevacizumab; Biomarkers; Cells, Cultured; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation; Histone Deacetylases; Humans; Hydroxamic Acids; Macular Degeneration; Retinal Pigment Epithelium; Vascular Endothelial Growth Factor A | 2021 |